Wall Street analysts expect that Luminex Co. (NASDAQ:LMNX) will announce earnings per share (EPS) of $0.08 for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Luminex’s earnings. The lowest EPS estimate is $0.03 and the highest is $0.13. Luminex reported earnings per share of $0.25 during the same quarter last year, which suggests a negative year-over-year growth rate of 68%. The business is expected to report its next quarterly earnings results after the market closes on Monday, November 5th.

According to Zacks, analysts expect that Luminex will report full-year earnings of $0.56 per share for the current year, with EPS estimates ranging from $0.50 to $0.63. For the next fiscal year, analysts forecast that the company will report earnings of $0.62 per share, with EPS estimates ranging from $0.41 to $0.74. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Luminex.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, August 6th. The medical instruments supplier reported $0.15 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.04). Luminex had a net margin of 10.57% and a return on equity of 7.44%. The business had revenue of $79.60 million during the quarter, compared to analyst estimates of $79.66 million. During the same period in the previous year, the company posted $0.26 earnings per share. Luminex’s revenue was up 4.1% compared to the same quarter last year.

A number of brokerages have weighed in on LMNX. Zacks Investment Research raised shares of Luminex from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. ValuEngine raised shares of Luminex from a “buy” rating to a “strong-buy” rating in a research note on Monday, October 29th. BidaskClub raised shares of Luminex from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $27.00 price objective on shares of Luminex in a research note on Tuesday, August 7th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Luminex currently has a consensus rating of “Buy” and a consensus price target of $28.60.

Shares of NASDAQ LMNX opened at $29.94 on Monday. Luminex has a twelve month low of $18.62 and a twelve month high of $35.37. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of 32.90, a price-to-earnings-growth ratio of 3.45 and a beta of 0.34.

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 12th. Shareholders of record on Friday, September 21st were paid a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend was Thursday, September 20th. Luminex’s dividend payout ratio is presently 26.37%.

Several institutional investors and hedge funds have recently modified their holdings of the company. Virginia Retirement Systems ET AL acquired a new position in shares of Luminex in the 3rd quarter valued at about $297,000. Wedge Capital Management L L P NC increased its holdings in shares of Luminex by 18.3% in the 3rd quarter. Wedge Capital Management L L P NC now owns 17,827 shares of the medical instruments supplier’s stock valued at $540,000 after purchasing an additional 2,756 shares during the period. US Bancorp DE increased its holdings in shares of Luminex by 4,090.5% in the 3rd quarter. US Bancorp DE now owns 11,063 shares of the medical instruments supplier’s stock valued at $335,000 after purchasing an additional 10,799 shares during the period. Hussman Strategic Advisors Inc. increased its holdings in shares of Luminex by 94.3% in the 3rd quarter. Hussman Strategic Advisors Inc. now owns 103,000 shares of the medical instruments supplier’s stock valued at $3,122,000 after purchasing an additional 50,000 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of Luminex by 3.7% in the 3rd quarter. Acadian Asset Management LLC now owns 1,635,083 shares of the medical instruments supplier’s stock valued at $49,560,000 after purchasing an additional 58,487 shares during the period. Institutional investors own 82.36% of the company’s stock.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Featured Story: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Luminex (LMNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.